BH-30643 — FDA meeting
Q4 2026
Q4 2026: End of Phase 1 meeting regarding a recommended Phase 2 dose selection and a potential accelerated approval pathway in C797S resistanceSource filing
BLSM biotech catalysts & pipeline
BLOSSOMHILL THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
BH-30236 — Interim data
1H 2027
1H 2027: Updated Phase 1 data on safety and anti-leukemic effectSource filing
BH-30643 — Interim data
1H 2027
1H 2027: Updated Phase 1 data, including C797S durabilitySource filing
BH-501284 — IND submission
Q1 2027
Q1 2027: Investigational New Drug submissionSource filing
BH-30643 — Interim data
2H 2027
2H 2027: Updated Phase 1 data on TKI-naive durability and initial chemo combo cohort dataSource filing